LightWave Acquisition Corp. Class A Ordinary Shares (LWAC)

Shares of Locust Walk Acquisition Corp (NASDAQ: LWAC) are surging higher Wednesday morning after the merger with eFFECTOR Therapeutics was approved. eFFECTOR Therapeutics is focused on selective translation regulation inhibitors to treat cancer. The SPAC merger valued the company at $419 million, including a $60 million PIPE with an investment...